$34.41
Price
$40.1B
Market Cap
28.4
P/E Ratio
11.1
Forward P/E
$1.21
EPS (TTM)
—
Dividend Yield
$3.6B
Cash
$17.1B
Total Debt
1.16B
Shares Out
$12.47
$37.35
52-Week Range
Institutional Ownership of TEVA PHARMACEUTICAL-SP ADR
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
|
Sound Shore Management|Harry Burn
|
4.3M | $135M | $10.35 | +205.89% |
Trading Activity for TEVA PHARMACEUTICAL-SP ADR
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2025-Q4 | |||||
| SELL | -23.7% | 4.3M | $135M | $24.59 | |
| 2025-Q3 | |||||
| SELL | -78.3% | 2.5M | $51M | $17.54 | |
| SELL | -3.4% | 5.6M | $114M | $17.54 | |
| 2025-Q2 | |||||
| BUY | +15.4% | 11.7M | $196M | $16.87 | |
| BUY | +7.2% | 5.8M | $98M | $16.87 | |
| 2025-Q1 | |||||
| BUY | +55.7% | 10.1M | $156M | $16.78 | |
| BUY | +14.2% | 5.5M | $84M | $16.78 | |
| SELL | EXIT | — | — | $16.78 | |
| SELL | EXIT | — | — | $16.78 | |
| 2024-Q4 | |||||
| SELL | -14.1% | 6.5M | $143M | $17.53 | |
| SELL | -20.1% | 4.8M | $105M | $17.53 | |
| 2024-Q3 | |||||
| BUY | NEW | 7.6M | $136M | $17.46 | |
| SELL | -11.6% | 6.0M | $108M | $17.46 | |
| 2024-Q2 | |||||
| SELL | -9.8% | 6.8M | $110M | $16.25 | |
| SELL | -5.6% | 10.9K | $177937 | $16.25 | |
| 2024-Q1 | |||||
| SELL | -16.0% | 7.5M | $106M | $12.92 | |
| SELL | EXIT | — | — | $12.92 | |
| SELL | -13.4% | 11.6K | $163676 | $12.92 | |
| 2023-Q4 | |||||
| BUY | +12.6% | 8.9M | $93M | $9.27 | |
| SELL | -24.7% | 6.0M | $63M | $9.27 | |
| SELL | -20.0% | 100.0K | $1M | $9.27 | |
| SELL | -5.8% | 13.4K | $139896 | $9.27 | |
| 2023-Q3 | |||||
| BUY | NEW | 7.9M | $81M | $9.61 | |
| SELL | -59.2% | 125.0K | $1M | $9.61 | |
| SELL | -82.7% | 14.2K | $145095 | $9.61 | |
| 2023-Q2 | |||||
| SELL | -97.9% | 82.1K | $618492 | $8.13 | |
| SELL | -51.1% | 306.1K | $2M | $8.13 | |
| 2023-Q1 | |||||
| SELL | -50.0% | 8.0M | $71M | $10.02 | |
| SELL | -23.6% | 3.9M | $35M | $10.02 | |
| SELL | -24.8% | 626.0K | $6M | $10.02 | |
| 2022-Q4 | |||||
| SELL | -33.3% | 15.9M | $145M | $8.70 | |
| SELL | -44.4% | 5.1M | $47M | $8.70 | |
| SELL | -29.1% | 832.6K | $8M | $8.70 | |
| 2022-Q3 | |||||
| SELL | -0.6% | 23.9M | $193M | $8.93 | |
| SELL | -0.8% | 9.3M | $75M | $8.93 | |
| SELL | -1.5% | 1.2M | $9M | $8.93 | |
| 2022-Q2 | |||||
| SELL | -7.2% | 9.3M | $70M | $8.60 | |
| BUY | +19.2% | 1.2M | $9M | $8.60 | |
| 2022-Q1 | |||||
| BUY | +4.0% | 10.1M | $94M | $8.39 | |
| BUY | +33.5% | 1.0M | $9M | $8.39 | |
| 2021-Q4 | |||||
| SELL | EXIT | — | — | $8.99 | |
| SELL | -0.9% | 9.7M | $77M | $8.99 | |
| 2021-Q3 | |||||
| SELL | -10.8% | 9.8M | $95M | $9.35 | |
| 2021-Q2 | |||||
| BUY | +3.6% | 10.9M | $108M | $10.56 | |
| 2021-Q1 | |||||
| BUY | +47.8% | 10.6M | $122M | $11.34 | |
| 2020-Q4 | |||||
| SELL | -11.7% | 7.1M | $69M | $9.53 | |
| 2020-Q3 | |||||
| BUY | +3.1% | 8.1M | $73M | $11.35 | |
| 2020-Q2 | |||||
| SELL | -0.9% | 7.9M | $97M | $11.38 | |
| 2020-Q1 | |||||
| SELL | -1.1% | 42.8M | $384M | $10.27 | |
| SELL | -24.1% | 7.9M | $71M | $10.27 | |
| SELL | EXIT | — | — | $10.27 | |
| 2019-Q4 | |||||
| BUY | +14.8% | 10.4M | $102M | $9.49 | |
| 2019-Q3 | |||||
| BUY | +33.2% | 24.0M | $165M | $7.54 | |
| BUY | +29.9% | 9.1M | $63M | $7.54 | |
| 2019-Q2 | |||||
| BUY | +54.1% | 7.0M | $65M | $11.86 | |
| 2019-Q1 | |||||
| SELL | -2.6% | 18.0M | $283M | $17.40 | |
| BUY | +16.1% | 4.5M | $71M | $17.40 | |
| 2018-Q4 | |||||
| SELL | -5.1% | 18.5M | $286M | $21.38 | |
| BUY | +0.2% | 3.9M | $60M | $21.38 | |
| 2018-Q3 | |||||
| SELL | -1.1% | 19.5M | $421M | $23.27 | |
| BUY | +50.9% | 3.9M | $84M | $23.27 | |
| 2018-Q2 | |||||
| BUY | +6.7% | 43.2M | $1.1B | $20.63 | |
| BUY | +17.9% | 2.6M | $63M | $20.63 | |
| 2018-Q1 | |||||
| BUY | +114.8% | 40.5M | $693M | $19.37 | |
| BUY | +325.3% | 2.2M | $38M | $19.37 | |
Insider Trading for TEVA PHARMACEUTICAL-SP ADR
6 Months Insider Sentiment
Buy $21K
Sell $20.1M
1
Buys
10
Sells
-20.1M
Net
0
Grants
Largest
$4.8M
Mignone
$3.4M
Sabag
$3.3M
Daniell
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 16, 2025 | Roberto Mignone | Director | SELL | 77.4K | $30.24 | $2.3M |
| Dec 16, 2025 | Amir Weiss | Chief Accounting Officer | SELL | 12.3K | $30.20 | $372K |
| Dec 09, 2025 | Mark Sabag | See "Remarks" | SELL | 98.2K | $28.70 | $2.8M |
| Dec 09, 2025 | Mark Sabag | See "Remarks" | EXERCISE | 118.7K | $18.61 | $2.2M |
| Dec 09, 2025 | Mark Sabag | See "Remarks" | SELL | 118.7K | $28.75 | $3.4M |
| Dec 09, 2025 | Richard Daniell | Exec. VP, European Commercial | EXERCISE | 15.0K | $16.99 | $255K |
| Dec 09, 2025 | Richard Daniell | Exec. VP, European Commercial | EXERCISE | 100.5K | $18.61 | $1.9M |
| Dec 09, 2025 | Richard Daniell | Exec. VP, European Commercial | SELL | 115.5K | $28.68 | $3.3M |
| Dec 02, 2025 | Chen Lichtenstein | Director | EXERCISE | 4.8K | — | — |
| Nov 26, 2025 | Roberto Mignone | Director | SELL | 50.0K | $26.03 | $1.3M |
| Nov 20, 2025 | Christine Fox | EVP, Head of U.S. Commercial | SELL | 28.2K | $24.78 | $700K |
| Nov 14, 2025 | Christine Fox | EVP, Head of U.S. Commercial | SELL | 30.0K | $25.11 | $753K |
| Nov 06, 2025 | Amir Weiss | Chief Accounting Officer | SELL | 12.3K | $24.44 | $301K |
| Nov 06, 2025 | Roberto Mignone | Director | SELL | 200.0K | $24.11 | $4.8M |
| Sep 05, 2025 | David R. Mcavoy | EVP, Chief Legal Officer | BUY | 1.1K | $18.86 | $21K |